Previous close | 1.3500 |
Open | 1.3200 |
Bid | 1.2800 x 2800 |
Ask | 1.3100 x 2800 |
Day's range | 1.2700 - 1.3600 |
52-week range | 0.4100 - 1.7500 |
Volume | |
Avg. volume | 2,430,119 |
Market cap | 242.376M |
Beta (5Y monthly) | 0.91 |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
Nektar (NKTR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
The placebo-controlled, phase IIb study will investigate the efficacy and safety of Nektar's (NKTR) rezpeg in patients with severe to very severe alopecia areata.
Nektar (NKTR) reports a wider-than-expected loss in the fourth quarter of 2023 while revenue beat estimates.